Similar articles

• PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls.

  Shields AF. Shields AF. J Nucl Med. 2003 Sep;44(9):1432-4. J Nucl Med. 2003. PMID: 12960188 No abstract available.
• Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.

  Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Muzi M, et al. J Nucl Med. 2005 Feb;46(2):371-80. J Nucl Med. 2005. PMID: 15695799
• The role of 18F-FLT in cancer imaging: does it really reflect proliferation?

  Dimitrakopoulou-Strauss A, Strauss LG. Dimitrakopoulou-Strauss A, et al. Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):523-6. doi: 10.1007/s00259-007-0679-8. Eur J Nucl Med Mol Imaging. 2008. PMID: 18183395 No abstract available.
• Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.

  Herrmann K, Buck AK. Herrmann K, et al. PET Clin. 2014 Jul;9(3):331-8. doi: 10.1016/j.cpet.2014.03.005. Epub 2014 Apr 26. PET Clin. 2014. PMID: 25030396 Review.
• (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

  Vallabhajosula S. Vallabhajosula S. Semin Nucl Med. 2007 Nov;37(6):400-19. doi: 10.1053/j.semnuclmed.2007.08.004. Semin Nucl Med. 2007. PMID: 17920348 Review.